Explore our kidney trials and find opportunities to take part in advancing medical research. Listings change as protocols open and close.
Study-related visits, tests, and investigational therapy are provided at no cost, and your insurance is never billed.
Baxdrostat in combination with dapagliflozin, evaluated for renal outcomes and cardiovascular mortality in chronic kidney disease.
Extended TARPEYO® (delayed-release budesonide) treatment in adults with primary IgA nephropathy.
An investigational agent alongside standard of care, evaluated for safety and efficacy in reducing albuminuria.
Retatrutide's effect on cardiovascular and kidney outcomes in adults living with obesity.
Lepodisiran for cardiovascular risk reduction in participants with high lipoprotein(a).
These studies continue with participants already enrolled.
FIND-CKD — finerenone evaluated for slowing the progression of non-diabetic chronic kidney disease.
ZEUS — ziltivekimab's effect on cardiovascular outcomes in people with atherosclerotic disease, CKD, and inflammation.
From the trial programs behind finerenone, dapagliflozin, daprodustat, and tolvaptan to today's next-generation molecules.
Call our study team. We will review your health history against the open protocols and tell you plainly whether one is a fit — with no cost and no obligation.